Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples.
Jean-Baptiste Bachet , Séverine Tabone-Eglinger , Sophie Dessaux , Anthony Besse
PLOS ONE 8 ( 4)
11
2013
Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA
Nicolas Pecuchet , Yves Rozenholc , Eleonora Zonta , Daniel Pietrasz
Clinical Chemistry 62 ( 11) 1492 -1503
42
2016
Adénocarcinomes du pancréas borderline et localement avancés réséqués après chimiothérapie néo-adjuvante par Folfirinox : résultats d’une étude multicentrique AGEO/FRENCH
Daniel Pietrasz , Lysiane Marthey , Mathilde Wagner , Antonio Sa-Cunha
Journal de Chirurgie Viscérale 151 ( 4) A28
2014
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.
Emmanuel Mitry , Astrid Lièvre , Jean-Baptiste Bachet , Philippe Rougier
International Journal of Colorectal Disease 24 ( 6) 605 -612
5
2009
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
David Malka , Eric François , Frédérique Penault-Llorca , Florence Castan
European Journal of Cancer 115 97 -106
7
2019
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Pascal Hammel , Portales Fabienne , Laurent Mineur , Jean-Philippe Metges
European Journal of Cancer 124 91 -101
20
2020
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101].
Pascal Hammel , Fabienne Portales , Laurent Mineur , Jean-Philippe Metges
European Journal of Cancer 130 275 -276
2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Yves Rinaldi , Anne-Laure Pointet , Faiza Khemissa Akouz , Karine Le Malicot
European Journal of Cancer 136 25 -34
2020
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Christine Tchikladze , Claire Garnier Tixidre , Jérôme Long , Manel Zaidi
European Journal of Cancer 141 62 -81
119
2020
Mo1520 EUS Fine Needle Aspiration and Biopsy Sample Quality Analysis for Hent1 Immunohistochemical Staining in Pancreatic Cancer Management
Puleo Francesco , RaphaëL MaréChal , Pieter Demetter , Laurine Verset
Gastrointestinal Endoscopy 77 ( 5) AB412
1
2013
Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Gilles Manceau , Sandrine Imbeaud , Raphaële Thiébaut , François Liébaert
Clinical Cancer Research 20 ( 12) 3338 -3347
68
2014
Sonic Hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma
Raphaël Maréchal , Jean-Baptiste Bachet , Annabelle Calomme , Pieter Demetter
Clinical Cancer Research 21 ( 5) 1215 -1224
47
2015
Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
Daniel Pietrasz , Nicolas Pécuchet , Fanny Garlan , Audrey Didelot
Clinical Cancer Research 23 ( 1) 116 -123
126
2017
Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution
Benjamin Le Calvé , Audrey Griveau , David Vindrieux , Raphaël Maréchal
Oncotarget 7 ( 22) 32100 -32112
26
2016
Abstract A238: c-MET as a target for MET inhibitors in patients with poor prognostic pancreatic adenocarcinoma following completed surgical resection.
Cindy Neuzillet , Jérôme Cros , Annemilaï Tijeras-Raballand , Julien Moroch
Molecular Cancer Therapeutics 12
2013
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.
Francesco Puleo , Rémy Nicolle , Yuna Blum , Jérôme Cros
Gastroenterology 155 ( 6) 1999
132
2018
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
Raymond Karkouche , Jean-Baptiste Bachet , Jeremy Sandrini , Emmanuel Mitry
European Journal of Gastroenterology & Hepatology 24 ( 12) 1430 -1437
40
2012
miRNA expression as a predictor of survival in patients with metastatic colorectal cancer treated with EGFR inhibitors.
Sandrine Imbeaud , Gilles Manceau , Jean-Baptiste Bachet , Jean-François Emile
Journal of Clinical Oncology 30 ( 15_suppl) e14059 -e14059
2012
Pharmacogenetic study in metastatic colorectal cancer (CRC) patients receiving third-line panitumumab-irinotecan: A GERCOR ancillary study.
Marie-Christine Etienne-Grimaldi , Laurence Llorca , Patricia Formento , Benoist Chibaudel
Journal of Clinical Oncology 30 2537 -2537
2012
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal , Simon Pernot , David Tougeron , Claire Arbaud
British Journal of Cancer 113 ( 7) 989 -995
169
2015